Other Events ·
Pulse Biosciences, Inc. announced the completion of patient enrollment in its PRECISE-BTN clinical study on September…
PLSEPulse Biosciences, Inc.
Pulse Biosciences, Inc. announced the completion of patient enrollment in its PRECISE-BTN clinical study on September 15, 2026, following an expansion from 50 to 100 patients across three U.S. sites: Sarasota Memorial Health Care System, NYU Langone Health, and Weill Cornell Medicine. The first enrolled patient completed their final 12-month follow-up visit in August 2026. The study evaluates the nPulse Vybrance Percutaneous Electrode System for treating symptomatic benign thyroid nodules, with endpoints including safety, volume reduction, and quality of life improvements. Pulse Biosciences is a medical device company developing nanosecond pulsed field ablation technology.